Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide.
Applications, Medical uses & Side effects
Explore the main themes, entities and connections around Lanreotide. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
somatostatin treatment used tumors acromegaly fda name neuroendocrine several united acetate medical effects us release somatuline administration 30 analogue also
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Lanreotide | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Lanreotide | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Lanreotide | ATC code | H01CB03 (WHO) | 1.00 | infobox |
| Lanreotide | Bioavailability | Approximately 80% | 1.00 | infobox |
| Lanreotide | CAS Number | 108736-35-2 N | 1.00 | infobox |
| Lanreotide | ChEMBL | ChEMBL1201185 N | 1.00 | infobox |
| Lanreotide | ChemSpider | 64450 Y | 1.00 | infobox |
| Lanreotide | CompTox Dashboard (EPA) | DTXSID60897514 | 1.00 | infobox |
| Lanreotide | DrugBank | DB06791 | 1.00 | infobox |
| Lanreotide | ECHA InfoCard | 100.215.992 | 1.00 | infobox |
| Lanreotide | Elimination half-life | 2 hours (immediate release) 5 days (sustained release) | 1.00 | infobox |
| Lanreotide | Excretion | Mostly bile duct | 1.00 | infobox |
| Lanreotide | Formula | C54H69N11O10S2 | 1.00 | infobox |
| Lanreotide | IUPHAR/BPS | 2031 | 1.00 | infobox |
| Lanreotide | KEGG | D04666 | 1.00 | infobox |
| Lanreotide | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Lanreotide | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Lanreotide | Legal status | US: ℞-only | 1.00 | infobox |
| Lanreotide | License data | US DailyMed: Lanreotide | 1.00 | infobox |
| Lanreotide | License data | US FDA: Lanreotide | 1.00 | infobox |
| Lanreotide | Metabolism | In GI tract | 1.00 | infobox |
| Lanreotide | Molar mass | 1096.33 g·mol−1 | 1.00 | infobox |
| Lanreotide | Other names | Lanreotide acetate (JAN JP), Lanreotide acetate (USAN US) | 1.00 | infobox |
| Lanreotide | Pregnancy category | AU: C | 1.00 | infobox |
| Lanreotide | Protein binding | 78% | 1.00 | infobox |
| Lanreotide | PubChem CID | 71349 | 1.00 | infobox |
| Lanreotide | Routes of administration | Intramuscular, subcutaneous | 1.00 | infobox |
| Lanreotide | Trade names | Somatuline | 1.00 | infobox |
| Lanreotide | UNII | 0G3DE8943Y | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.